Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice
Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice
复制标题
DOI：
10.1016/j.cca.2019.04.081
复制
发表时间：
2019-08-01
影响因子：
5
通讯作者：
Peoc'h, K.
中科院分区：
文献类型：
--
作者：
Lehmann, S.;Paquet, C.;Peoc'h, K.
背景：脑脊液 (CSF) 生物标志物是诊断神经系统疾病的宝贵工具。我们的目的是在一项回顾性多中心研究中调查与非常高的脑脊液 Tau 水平相关的最终诊断，并确定在临床实践中区分它们的生物标志物模式，以帮助临床生物学家为医生提供咨询。 患者和方法：在国家多中心网络 ePLM 中，我们纳入了 2008 年 1 月 1 日至 2013 年 12 月 31 日期间的 1743 名患者，其脑脊液生物标志物通过相同的 Innotest 检测（蛋白质Tau、磷酸化 Tau [pTau] 和 A beta 1-42）。我们确定了 205 名 Tau 蛋白浓度高于 1200 pg/mL 的患者并进行了最终诊断。结果：在这些患者中，105 名 (51.2%) 患有阿尔茨海默病，37 名 (18%) 患有散发性克雅氏病，63 名 (30.7%) 患有其他神经系统疾病，包括副肿瘤/中枢神经系统肿瘤、额颞叶痴呆、其他诊断、淀粉样血管病、路易体痴呆和中枢神经系统感染。 Phospho-Tau、A beta 1-42 和 A beta 1-42/pTau 值在三组患者之间存在显着差异 (p
Context: Cerebrospinal fluid (CSF) biomarkers are valuable tools for the diagnosis of neurological diseases. We aimed to investigate within a retrospective multicentric study the final diagnosis associated with very high CSF Tau levels and to identify patterns of biomarkers that would differentiate them in clinical practice, to help clinical biologists into physicians' counseling.Patients and methods: Within the national multicentric network ePLM, we included 1743 patients from January 1, 2008, to December 31, 2013, with CSF biomarkers assayed by the same Innotest assays (protein Tau, phospho-Tau [pTau], and A beta 1-42). We identified 205 patients with protein Tau concentration higher than 1200 pg/mL and final diagnosis.Results: Among those patients, 105 (51.2%) were suffering from Alzheimer's disease, 37 (18%) from sporadic Creurtfeldt-Jakob disease, and 63 (30.7%) from other neurological diseases including paraneoplastic/central nervous system tumor, frontotemporal dementia, other diagnoses, amyloid angiopathy, Lewy body dementia, and infections of the central nervous system. Phospho-Tau, A beta 1-42 and A beta 1-42/pTau values differed significantly between the three groups of patients (p